Understanding how certain immune cells contribute to autoimmune diseases
TLR7 and TLR9-directed plasma cell formation: Dissecting the molecular basis for their differential dependence on IFN-induced signals
This study is looking at how certain immune cells called B cells behave in autoimmune diseases like Rheumatoid Arthritis and Lupus, especially focusing on a special type of B cell to understand how they might create harmful antibodies that can make you feel worse.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-10877914 on NIH RePORTER |
What this research studies
This research investigates the role of specific immune cells, particularly B cells, in autoimmune diseases like Rheumatoid Arthritis and Systemic Lupus Erythematosus. It focuses on how these cells respond to signals from cytokines and TLR ligands, which are crucial for their development and function. By examining a unique subset of B cells known as DN2 cells, the research aims to uncover the mechanisms that lead to the production of harmful antibodies in autoimmune conditions. The study employs both laboratory experiments and patient-derived cells to explore these processes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with autoimmune diseases such as Rheumatoid Arthritis or Systemic Lupus Erythematosus.
Not a fit: Patients with autoimmune diseases who are already responding well to existing treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new therapies for patients suffering from autoimmune diseases.
How similar studies have performed: Other research has shown promise in understanding immune responses in autoimmune diseases, but this specific approach is relatively novel.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Lund, Frances E. — University of Alabama at Birmingham
- Study coordinator: Lund, Frances E.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.